Durable Response With Sequential Tyrosine Kinase Inhibitor Treatment in a Patient With ROS1 Fusion-Positive Pancreatic Adenocarcinoma: A Case Report

JCO Precis Oncol. 2023 Apr:7:e2200467. doi: 10.1200/PO.22.00467.
No abstract available

Publication types

  • Case Reports

MeSH terms

  • Adenocarcinoma* / drug therapy
  • Adenocarcinoma* / genetics
  • Humans
  • Lung Neoplasms*
  • Pancreatic Neoplasms* / drug therapy
  • Pancreatic Neoplasms* / genetics
  • Protein Kinase Inhibitors / pharmacology
  • Protein Kinase Inhibitors / therapeutic use
  • Protein-Tyrosine Kinases / genetics
  • Proto-Oncogene Proteins
  • Tyrosine Kinase Inhibitors

Substances

  • Protein-Tyrosine Kinases
  • Tyrosine Kinase Inhibitors
  • Proto-Oncogene Proteins
  • Protein Kinase Inhibitors
  • ROS1 protein, human